SCHEMBL278324

SCHEMBL278324

FC(F)(F)Oc1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.46
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
SLC6A4 P31645 2/20 0.43
GPR3 P46089 2/20 0.42
USP28 Q96RU2 1/20 0.42
USP25 Q9UHP3 1/20 0.42
KCNH2 Q12809 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
KIF11 P52732 2/20 0.41
CETP P11597 1/20 0.41
DDR1 Q08345 1/20 0.40
WDR5 P61964 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29351368 1.00 MAOB (0.46) MAOBALDH1A1GAAMAPTHPGD
SCHEMBL1410607 0.89 WDR5 (0.44) MAOBALDH1A1GAAMAPTHPGD
SCHEMBL31360383 0.87 CETP (0.43) MAOBALDH1A1GAAMAPTSLC6A4
Methane SCHEMBL27611218 0.86 DDR1 (0.42) MAOBALDH1A1GAAMAPTHPGD
SCHEMBL3147185 0.84 GPR3 (0.50) GPR3KIF11CETP
SCHEMBL11720083 0.83 MAOB (0.43) MAOBALDH1A1GAAMAPTHTT
SCHEMBL4875079 0.83 MAOB (0.43) MAOBALDH1A1GAAMAPTHTT
SCHEMBL27219499 0.83 MAOB (0.43) MAOBALDH1A1GAAMAPTHTT
SCHEMBL14157395 0.83 MAOB (0.43) MAOBALDH1A1GAAMAPTSLC6A4
SCHEMBL11721758 0.83 MAOB (0.40) MAOBALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2014-03-06 US claimed
EP-1999096-A2 PROCESS FOR THE PREPARATION OF 1-BROMO-3-TRIFLUOROMETHOXYBENZENE MITENI S.p.A. (IT) 2008-12-10 EP claimed
WO-2007107820-A2 PROCESS FOR THE PREPARATION OF 1-BROMO-3-TRIFLUOROMETHOXYBENZENE MITENI S.P.A. (IT) 2007-09-27 WO claimed
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-04-23 US disclosed
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2026-03-19 US disclosed
EP-4103557-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders JANSSEN PHARMACEUTICA NV (BE) 2025-12-23 US disclosed
EP-4661964-A1 COMPOUNDS AS CCR6 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-12-17 EP disclosed
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-11-20 US disclosed
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient DIGMBIO, Inc. (KR) 2025-11-04 US disclosed
EP-4384165-B1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2025-07-09 EP disclosed
US-6090833-A EATING DISORDERS; ANTIDIABETIC AGENT AVENTIS PHARMA DEUTSCHAND GMBH (DE) 2000-07-18 US disclosed
US-5929281-A REACTING A HETROCYCLIC AROMATIC HALIDE WITH AN AMINE COMPOUND IN PRESENCE OF A BASE USING A TRI-TERT-BUTYLPHOSPHINE AND PALLADIUM COMPOUND CATALYST TO FORM HETEROCYCLIC AROMATIC AMINE COMPOUNDS TOSOH CORPORATION (JP) 1999-07-27 US disclosed
US-5872136-A Arylheteroaryl inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-02-16 US disclosed
EP-0891361-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 EP disclosed
EP-0802173-A1 Process for producing heterocylic aromatic amine or arylamine Tosoh Corporation (JP) 1997-10-22 EP disclosed
WO-1997036901-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed
EP-0493650-A1 Fluorinated acetylene-containing aromatic amines and diamines National Starch and Chemical Investment Holding Corporation (US) 1992-07-08 EP disclosed
US-5107026-A Fluorinated acetylene-containing aromatic amines and diamines NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1992-04-21 US disclosed
US-4031119-A LUBRICANTS, GREASES, SEALS PONOMAREV ALEXEI IVANOVICH 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient PARP1, PARP2, PARP11 MAOB 1484/4885ALDH1A1 326/4885GAA 999/4885
US-12502378-B2 Monoacylglycerol lipase modulators for use in autism spectrum disorders LIPC, LPL, MGLL MAOB 62/4885ALDH1A1 266/4885GAA 60/4885
US-20250353859-A1 COMPOUNDS AS CCR6 INHIBITORS CCR6, CCR4, CCR1 MAOB 4262/4885ALDH1A1 3366/4885GAA 3474/4885
US-20260078116-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, MCL1 MAOB 4720/4885ALDH1A1 3887/4885GAA 3755/4885
US-20260109696-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS KRAS, MYC, NRAS MAOB 3910/4885ALDH1A1 3241/4885GAA 3640/4885
US-20140066369-A1 Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto GPR119, GLP1R, SLC5A2 MAOB 4460/4885ALDH1A1 1526/4885GAA 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.